GO
Loading...

Enter multiple symbols separated by commas

CNBC's Dan Scott: Novartis Drug Galvus Could be Delayed

Swiss pharmaceutical giant Novartis' plans to launch diabetes treatment Galvus may be dealt a blow by the Food and Drug Administration at the end of the month, market sources told CNBC Europe.

The FDA will ask for more clinical data on the 100 mg dose of Galvus, expected to be a blockbuster drug with sales of more than $1 billion, CNBC Europe's Dan Scott reported. Only the 50 mg dose will be allowed to market.

If the FDA does proceed in that fashion "it would basically mean that there's not much sense in launching this drug in 2007, or rather until there is an OK for both applications," Scott said.

If that happens, the entire analysts' community will have to change earnings forecasts for the company, due to a major delay in expected revenues, he added.

Galvus approval was already delayed by regulators' requests for more data in November.

Shares of Novartis, already down recently on analyst speculation of a delay, fell a further 1%.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • In a rare menu test, Chipotle is testing a Chorizo Burrito, a spicy sausage made with chicken and pork, in its Kansas City restaurants.

    In a relatively a rare move for Chipotle Mexican Grill, Chipotle began testing a new menu item Tuesday.

  • A prototype of a Diebold bank branch of the future.

    Big banks are spending on futuristic branches, but it's all a waste of time and money, say financial technology experts.

  • Nouriel Roubini

    Nouriel Roubini explains how and why more economic liquidity may have led to "severe market illiquidity."

U.S. Video